LOGIN  |  REGISTER
Chimerix
C4 Therapeutics

Akoya Biosciences to Participate at Three Upcoming Investor Conferences

November 02, 2023 | Last Trade: US$2.16 0.00 0.00

MARLBOROUGH, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that Company management will be participating in three upcoming investor conferences.

  • Stephens Annual Investment Conference | NASH 2023
    Fireside Chat on Wednesday, November 15th at 11:00 AM CT
    Nashville, TN
  • Canaccord Genuity 2023 MedTech, Diagnostics and Digital Health & Services Forum
    Fireside Chat on Thursday, November 16th at 2:30 PM ET
    New York, NY
  • Piper Sandler 35th Annual Healthcare Conference
    Fireside Chat on Thursday, November 30th at 11:30 AM ET       
    New York, NY

A live and archived webcast of the events will be available on the “Investors” section of the Akoya website at https://investors.akoyabio.com/.

About Akoya Biosciences

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research via its key platforms: PhenoCycler™, PhenoImager™ Fusion and PhenoImager HT. To learn more about Akoya, visit www.akoyabio.com.

Investor Contact:
Priyam Shah
Sr. Director, Investor Relations
Akoya Biosciences, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact:
Christine Quern
(617) 650-8497
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Assertio

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB